<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03327727</url>
  </required_header>
  <id_info>
    <org_study_id>VL2397-201</org_study_id>
    <secondary_id>2017-003435-11</secondary_id>
    <nct_id>NCT03327727</nct_id>
  </id_info>
  <brief_title>VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults</brief_title>
  <official_title>A Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Adults With Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, or Allogeneic Hematopoietic Cell Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to evaluate the safety and efficacy of a new antifungal with a
      novel mechanism of action in immunocompromised adults with invasive aspergillosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the safety and efficacy of VL-2397 to standard first-line treatment for invasive
      aspergillosis in immunocompromised adults with acute leukemia or recipients of an allogeneic
      hematopoietic cell transplant (allo-HCT).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The Sponsor, safety monitoring board, and data review committee are masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality (ACM)</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACM</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of participants with adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Invasive Aspergillosis</condition>
  <condition>Invasive Pulmonary Aspergillosis</condition>
  <arm_group>
    <arm_group_label>VL-2397</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational agent VL-2397 600 mg IV infusion administered every day for 28 days (4 weeks) followed by 2 weeks of standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard (First-Line) Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Investigator selected standard treatments of voriconazole, isavuconazole, or liposomal amphotericin B administered every day for 42 days (6 weeks) per product package insert</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Investigational Agent: VL-2397</intervention_name>
    <description>VL-2397</description>
    <arm_group_label>VL-2397</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B</intervention_name>
    <description>Voriconazole, Isavuconazole, or Liposomal amphotericin B</description>
    <arm_group_label>VL-2397</arm_group_label>
    <arm_group_label>Standard (First-Line) Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute Leukemia (AML or ALL) patient or allo-HCT recipient with a diagnosis of IA

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  IA involving sites other than lungs and sinuses

          -  Graft failure, acute or extensive chronic GvHD

          -  Uncontrolled diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mammen P Mammen, MD, FIDSA</last_name>
    <role>Study Director</role>
    <affiliation>Vical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>VL2397-201 Team</last_name>
    <phone>858.646.1100</phone>
    <email>info@vical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical College of Georgia at Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aprile Osborn, RN</last_name>
      <phone>706-721-0309</phone>
      <email>aosborn@augusta.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelbie Martin</last_name>
      <phone>713-500-6761</phone>
      <email>shelbie.a.martin@uth.tmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2017</study_first_submitted>
  <study_first_submitted_qc>October 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2017</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
    <mesh_term>Pulmonary Aspergillosis</mesh_term>
    <mesh_term>Invasive Pulmonary Aspergillosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

